PSA Doubling Times and Prostate Cancer Relapse

Table of Contents
View All
Table of Contents

If you or someone you're close to has prostate cancer, you'll hear a lot about the PSA blood test and the PSA doubling time (PSADT). PSA helps medical providers screen for and diagnose prostate cancer at an early stage.

But there's more to the test than just that. The PSADT—a measurement of how quickly the PSA is increasing—is especially important after you've been treated for prostate cancer.

This article will walk you through why the PSA doubling time is so significant, how your doctors will use it to monitor for recurrence, and what factors will play a role in how a recurrence is treated.

What is PSA?

PSA stands for prostate-specific antigen. It's a protein produced by cells in the prostate gland. The PSA test measures levels of this protein in the blood. High levels can be a sign of prostate cancer.

Radiologist consoling a patient at MRI scan.
skynesher / Getty Images

Why PSA Is Important

PSA plays many different roles. The most common is determining prostate cancer risk.

PSA Levels and Prostate Cancer Risk
Low <10
Intermediate 10-20
High >20

PSA is also used to help determine the stage of a newly diagnosed prostate cancer. Staging is a measurement of how advanced the disease is.

The PSA doubling time can also detect a relapse of cancer after treatment with surgery or radiation.

The time it takes for PSA blood levels to double gives your medical team an insight into how aggressive your prostate cancer will be in the future. 

That can guide your treatment plan, which may include:


The PSA and PSADT are important for prostate cancer screening, diagnosis, and—in the case of a relapse—determining the best treatment plan.

Detecting a Relapse

PSA is useful for detecting a relapse of prostate cancer after surgery or radiation. After prostate cancer surgery, PSA is normally undetectable, and even small rises could point to a recurrence. 

After curative radiation, the PSA generally stays under 1.0 long-term. However, there are exceptions. Sometimes, the PSA level drops slowly after radiation and it may take years to reach its lowest point.

Younger people may have a short-term PSA rise that's not cancer-related. That's more common after the seed-implant type of radiation. This temporary rise is called a "PSA bump" or "bounce." It can develop between one and four years after treatment.

It may be linked with anti-cancer activity in the immune system, which is a good thing. However, it's sometimes mistaken for a recurrence, which can lead to fear, stress, and even unnecessary hormone therapy. 

What Guides Treatment

When cancer comes back, the PSADT is an indicator of how fast it's growing.

Ultimately, relapse treatment is guided by: 

  • The PSADT
  • Your original (pre-treatment) risk category
  • The tumor's location
  • Whether you originally had surgery or radiation

Your age, other illnesses, and overall health will also be considered.


The PSA doubling time has a big influence on treatment. There are treatments for men whose prostate cancer had recurred and is getting worse despite anti-hormonal treatment with Lupron Depot.

Treatments for recurrence of prostate cancer that hasn't spread:

  • PSADT of 10+ months: Observation is generally preferred. Secondary hormone therapy can be considered.
  • PSADT of three to 10 months: Treatment with Erleada (apalutamide), Nubeqa (darolutamide), or Xtandi (enzalutamide) is preferred. Additional secondary hormone therapy is also recommended.
  • PSADT of three months or less: Treatment should be aggressive, such as six cycles of Taxotere (docetaxel) along with Lupron Depot. Some medical providers may consider new drugs like Zytiga (abiraterone acetate), Xtandi, or Orgovyx (relugolix).

Original Risk Category

Your original risk category will also play a role in treatment decisions.

Risk categories:

  • Low risk: Cancer is confined to the prostate, PSA is less than 10 and grade group 1, or the tumor is very slow-growing.
  • Intermediate risk: Cancer is confined to the prostate, PSA is between 10 and 20, or grade group 2 or 3.
  • High risk: Cancer extends outside the prostate, PSA is higher than 20, or grade group 4 o r 5; or the tumor is very aggressive and has spread to other areas.

The higher the risk, the more aggressive the treatment. For example, if you were originally low risk, your treatment may include either cryotherapy, radiation, or Lupron Depot alone if cancer is confined to the prostate (after radiation) or the prostatic bed (after prior surgery).

If you were originally in the high-risk category, treatment may mean Lupron Depot plus pelvic lymph node radiation.


After surgery or radiation, medical providers watch for a cancer relapse with PSA and PSADT test results. Those numbers plus your original risk category are considered together when deciding what treatment course to follow—the faster the PSADT and the higher your risk category, the more aggressive treatment will be.

Tumor Location

If you have a rising PSA after surgery or radiation, your doctor will likely order imaging studies to find the location of your cancer recurrence.

Common scans are:

Cancer in the prostate or prostate bed is considered a local recurrence. Cancer that's spread outside of that area is called metastatic.

Treatment of metastatic recurrence depends on where it is and many other factors.

With a local relapse, disease suppression with Lupron Depot is an option.

That's especially true if you have a:

  • High PSA
  • Short PSADT
  • Otherwise long life expectancy

Lupron Depot alone is almost never a cure, but it often controls the disease for more than a decade.

Insurance Coverage

Some of the newer, more accurate PET scans may not be covered by your insurance. Be sure to check on your coverage before you opt for one of these expensive tests.


Generally, if you were low-risk or intermediate-risk before surgery and develop a PSADT of between six and 12 months, your recurrence has a good chance of being cured with radiation treatment to the prostate bed.

Radiation is most effective when the PSA level is low and the PSADT is long without evidence of spread/metastases on imaging studies.

If you want to avoid radiation side effects, another option is to suppress the PSA with an intermittent, six-month course of Lupron Depot.

If your PSA doubling time is faster—for example, under six months—your medical provider is likely to recommend pelvic-node radiation plus Lupron Depot for as long as 12 to 18 months.

If you were high-risk before surgery, treatment will often be node radiation with 12 to 18 months of Lupron Depot. Your medical provider may suggest adding more powerful drugs like Zytiga, Xtandi, or Taxotere.


For a rising PSA after radiation, a popular approach is cryosurgery (freezing cancer cells). Newer scans help the cryosurgeon focus on cancerous areas, rather than treating the whole prostate. 

This is called focal cryotherapy. It offers much fewer side effects than freezing or removing the whole gland.

Another alternative is prompt treatment with Lupron Depot. This can suppress the local disease.

It's considered reasonable when:

  • The PSADT is longer than six months
  • The original risk category was either low or intermediate

If you were originally high risk, a local relapse should be treated aggressively with cryosurgery or seed implantation. Lupron Depot alone is less likely to work.

The prostate is rarely removed after radiation, due to high rates of incontinence and erectile dysfunction. 


Oncologists and other medical providers use multiple scans, including some newer types, to find where cancer has recurred. Once it's located and there is no evidence of metastases, the PSA, PSADT, original risk category, and other factors are used to determine treatment.

Treatment courses depend largely on whether your original cancer was treated with surgery or radiation.

  • After surgery, radiation and Lupron Depot are options.
  • After radiation, cryotherapy or Lupron Depot are common choices.
  • Lupron Depot alone is recommended when PSA and PSADT indicate more aggressive cancer.


Deciding on a treatment for a PSA relapse is complex. The choice is based on factors including your original risk category, PSA doubling time, and scan findings. The location of recurrent cancer may remain uncertain, even with the best scans. 

Treatment with cryosurgery or radiation alone is reasonable when:

  • Scans indicate that cancer hasn't spread to the nodes.
  • The previous risk category was low or moderate.
  • The PSADT is long.

Microscopic metastases in the pelvic nodes don't always show up on scans. 

They're more likely if:

  • The PSADT is fast.
  • The previous risk category was high.

In these situations, pelvic lymph node radiation plus an extended course of Lupron Depot is usually recommended.

A Word From Verywell

Cancer is always serious, but the overall outlook of prostate cancer is often positive. Most people with prostate cancer have a good 15-year prognosis.

Sometimes, prostate cancer can be cured. Even when it's not, it can be controlled for years and even decades.

Keep up with your monitoring tests, including the PSA doubling time, is a key component of staying well in the long term.

12 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. National Institutes of Health, U.S. National Library of Medicine: MedlinePlus. Prostate-specific antigen (PSA) test

  2. National Institutes of Health, National Cancer Institute. Prostate-specific antigen (PSA) test.

  3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Prostate cancer, version 2.2021.

  4. Kishan AU. PSA bounce, prognosis, and clues to the radiation responseProstate Cancer Prostatic Dis. 2021;10.1038/s41391-021-00387-4. doi:10.1038/s41391-021-00387-4

  5. Schweizer MT, Huang P, Kattan MW, et al. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trialsCancer. 2013;119(20):3610-3618. doi:10.1002/cncr.28270

  6. Prostate Cancer Foundation. Risk groups.

  7. Songmen S, Nepal P, Olsavsky T, Sapire J. Axumin positron emission tomography: Novel agent for prostate cancer biochemical recurrence. J Clin Imaging Sci. 2019;9:49. doi:10.25259/JCIS_139_2019

  8. Kitajima K, Murphy RC, Nathan MA, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coilJ Nucl Med. 2014;55(2):223-232. doi:10.2967/jnumed.113.123018

  9. Gupta I, Freid B, Masarapu V, et al. Transrectal subharmonic ultrasound imaging for prostate cancer detectionUrology. 2020;138:106-112. doi:10.1016/j.urology.2019.12.025

  10. Artibani W, Porcaro AB, De Marco V, Cerruto MA, Siracusano S. Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int. 2018;100(3):251-262. doi:10.1159/000481438

  11. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyLancet. 2020;395(10231):1208-1216. doi:10.1016/S0140-6736(20)30314-7

  12. Ahdoot M, Lebastchi AH, Turkbey B, Wood B, Pinto PA. Contemporary treatments in prostate cancer focal therapyCurr Opin Oncol. 2019;31(3):200-206. doi:10.1097/CCO.0000000000000515

Additional Reading

By Mark Scholz, MD
Mark Scholz, MD, is a board-certified oncologist and expert on prostate cancer.